Gemcitabine in transitional cell carcinoma of the urothelium

Expert Review of Anticancer Therapy

Volumn 3, Issue 1, 2003, Pages 11-19

  von der Maase, Hans ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bladder cancer; Carcinoma; Chemotherapy; Gemcitabine; Transitional cell

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEOXYCYTIDINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; VINBLASTINE;

ADVANCED CANCER; ALOPECIA; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; FEVER; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LIVER TOXICITY; METASTASIS; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; PATIENT CARE; REVIEW; SEPSIS; STANDARD; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CARCINOMA; UROTHELIUM;

EID: 0037320912     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.1.11     Document Type: Review

References (59)

1. Plunkett W, Huang P, Searcy CE et al. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin. Oncol. 23(Suppl. 10), 3-15 (1996).
2. Storniolo AM, Allerheiligen SRB, Pearce HL. Preclinical, pharmacologic and Phase I studies of gemcitabine. Semin. Oncol. 24(Suppl-7), 2-7 (1997).
3. Gandhi V, Plunkett W, Du M et al. Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a Phase I trial in relapsed acute myelogenous leukemia. J. Clin. Oncol. 20, 665-673 (2002).
4. Roth BJ. Chemotherapy for advanced bladder cancer. Semin. Oncol. 23, 633-644, (1996).
5. Harker WG, Meyers FJ, Freiha FS et al. Cisplatin, methotrexate and vinblastine (CMV): an effective chemotherapy regime for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group Study. J. Clin. Oncol. 3, 1463-1470 (1985).
6. Sternberg CN, Yagoda A, Scher HI et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J. Urol. 133, 403-407 (1985).
7. Sternberg CN, Yagoda A, Scher HI et al. Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 64, 2448-2458 (1989).
8. Mead GM, Russell M, Clark P et al. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br. J. Cancer 78, 1067-1075 (1998).
9. Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J. Clin. Oncol. 17, 3173-3181 (1999).
10. Dodd PM, McCaffrey JA, Herr H et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J. Clin. Oncol. 17, 2546-2552, (1999).
11. Tannock I, Gospodarowicz M, Connolly J, Jewett M. MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience. J. Urol. 142, 289-292 (1989).
12. Connor JP, Olsson CA, Benson MC et al. Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern. Urology 34, 353-356 (1989).
13. Igawa M, Ohkuchi T, Ueki T et al. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J. Urol. 144, 662-665 (1990).
14. Boutan-Laroze A, Mahjoubi M, Droz JP et al. MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience. Eur. J. Cancer 27, 1690-1694 (1991).
15. Loehrer PJ Sr, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a co operative group study. J. Clin. Oncol. 10, 1066-1073 (1992).
16. Logothetis CJ, Dezeus FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. 8, 1050-1055 (1990).
17. Saxman SB, Propert KJ, Einhorn LH et al. Long-term follow-up of a Phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a co-operative group study. J. Clin. Oncol. 15, 2564-2569 (1997).
18. Seidman AD, Scher HI, Gabrilove JL et al. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial carcinoma. J. Clin. Oncol. 11, 408-414 (1993).
19. Loehrer PJ Sr, Elson P, Dreicer R et al. Escalated dosages of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma. An Eastern Co-operative Oncology Group trial. J. Clin. Oncol. 12, 483-488 (1994).
20. Logothetis CJ, Finn LD, Smith T et al. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J. Clin. Oncol. 13, 2272-2277 (1995).
21. Sternberg CN, de Mulder PH, Schornagel J et al. Randomized Phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no 30924. J. Clin. Oncol. 19, 2638-2646 (2001).
22. von der Maase H. Current and future perspectives in advanced bladder cancer: Is there a new standard? Semin. Oncol. 29(Suppl. 3), 3-14 (2002).
23. Pollera CF, Ceribelli A, Crecco M, Calabresi F. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a Phase I study. Ann. Oncol. 5, 182-184 (1994).
24. Lorusso V, Pollera CF, Antimi M et al. A Phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur. J. Cancer 34, 1208-1212 (1998).
25. Stadler WM, Kuzel T, Roth B et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J. Clin. Oncol. 15, 3394-3398 (1996).
26. Moore MJ, Tannock IF, Ernst DS et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J. Clin. Oncol. 15, 3441-3445 (1997).
27. Gebbia V, Testa A, Borsellino N et al. Single agent 2′, 2′-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a Phase II study. Clin. Ter. 150, 11-15 (1999).
28. Albers P, Siener R, Hartlein M et al. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life. Onkologie 25, 47-52 (2002).
29. Marenco D, Castagneto B, Zai S et al. Gemcitabine monochemotherapy in the elderly patient with advanced bladder cancer. Proc. Am. Soc. Clin. Oncol. 21, 150b (2002) (Abstract 2414).
30. Peters GJ, Bergman AM Ruiz, van Haperen VW et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol. 22, 72-79 (1995).
31. von der Maase H, Andersen L, Crinó L et al. Weddy gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothleium: a Phase II clinical trial. Ann. Oncol. 10, 1461-1465 (1999).
32. Kaufman D, Raghavan D, Carducci M et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J. Clin. Oncol. 18, 1921 1927 (2000).
33. Moore JM, Winquist EW, Murray N et al. Gemcitabine plus cisplatin, an active regime in advanced urothelial cancer: a Phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 17, 2876-2881 (1999).
34. Lorusso V, Manzione L, De Vita F et al. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a Phase II multicenter trial. J. Urol. 164, 53-56 (2000).
35. Wilson JJ, Winquist E, Dorreen M et al. A Phase II trial of gemcitabine plus day 1 cisplatin given on a 21 day schedule in patients with advanced unresectable or metastatic bladder cancer. Proc. Am. Soc. Clin. Oncol. 21, 151b (2002) (Abstract 2418).
36. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplarin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol 18, 3068-3077 (2000).
37. Stadler WM, Hayden A, von der Maase H et al. Long-term survival in Phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol. Oncol. 7, 153 157 (2002).
38. Fossa SD, Sternberg C, Scher HI et al. Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy. Br. J. Cancer 74, 1655-1659 (1996).
39. Sengelov L, Kamby C, Geertsen P et al. Predictive factors of response to cisplatin based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer. Cancer Chemother. Pharmacol. 46, 3 57-364 (2000).
40. Sengelov L, Kamby C, von der Maase H. Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years. Eur. Urol. 39, 634-642 (2001).
41. Sternberg CN, Calabró F, Pizzocaro, G et al. Chemotherapy with an every-2-week regime of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplarin-based therapy. Cancer 92, 2993-2998 (2001).
42. Kaufman DS, Carducci MA, Kuzel T et al. Gemcitabine (G) and paclitaxel (P) every two weeks (GP2W): a completed multicenter Phase II trial in locally advanced or metastatic urothelial cancer (UC). Proc. Am. Soc. Clin. Oncol. 21, 192a (2002) (Abstract 767).
43. Meluch AA, Greco FA, Burris HA III et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional cell carcinoma of the urothelial tract: a Phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 19, 3018-3024 (2001).
44. Pectasides D, Aravantinos G, Kalofonos H et al. Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A Phase II trial conducted by the Hellenic Co-operative Oncology Group. Ann. Oncol. 12, 1417-1422 (2001).
45. Nogué M, Carles J, Arrivi A et al. Palliative chemotherapy with gemcitabine (Gem) and carboplatin (CBDCA) in advanced transitional cell carcinoma of the urothelium (ATCCU). Preliminary results. Proc. Am. Soc. Clin. Oncol. 19, 345a (2000) (Abstract 1359).
46. Carles J, Nogué M, Domenech M et al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology 59, 24-27 (2000).
47. Hussain M, Vaishampayan U, Du W et al. Combination paclitaxel, carboplatin and gemcitabine is an active treatment for advanced urothelial cancer. J. Clin. Oncol. 19, 2527-2533 (2001).
48. Bellmunt J, Guillem V, Paz-Ares L et al. Phase I-II study of paclitaxel, cisplatin and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J. Clin. Oncol. 18, 3247-3255 (2000).
49. Bellmunt J, Albanell J, Paz-Ares L et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a Phase I/II trial with paclitaxel, cisplatin and gemcitabine. Cancer 95, 751 757 (2002).
50. Pectasides D, Glotsos J, Bountouroglou N et al. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a Phase II trial. Ann. Oncol. 13, 243-250 (2002).
51. Pagliaro LC, Millikan RE, Tu SM et al. Cisplatin, gemcitabine and ifosfamide as weekly therapy: a feasibility and Phase II study of salvage treatment for advanced transitional-cell carcinoma. J. Clin. Oncol. 20, 2965-2970 (2002).
52. Droz J-P, Fizazi K, Beuzeboc P et al. Gemcitabine and cisplatin (GC) as adjuvant chemotherapy for locally advanced bladder cancer (LABC) after cystectomy: preliminary results of a feasibility study. Proc. Am. Soc. Clin. Oncol. 153b (2002) (Abstract 2425).
53. Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization. Semin. Oncol. 24(Suppl. 7), 24-28 (1997).
54. Fields MT, Eisbruch A, Normolle D et al. Radiosensitization produced in vivo by once- vs. twice weekly 2′2′-difluoro-2′ deoxycytidine (gemcitabine). Int. J. Rad. Oncol. Biol. Phys. 47, 785-791 (2000).
55. Robinson BW, Shewach DS. Radiosensitization by gemcitabine in p53 wild type and mutant MCF-7 breast carcinoma cell lines. Clin. Cancer Res. 7, 2581-2589 (2001).
56. Lawrence TS, Davis MA, Hough A et al. The role of apoptosis in 2′,2′-difluoro-2′ deoxycytidine (gemcitabine)-mediated radiosensitization. Clin. Cancer Res. 7, 314 319 (2001).
57. Egorin MJ, Zuhowski EG, Laufer M et al. Plasma pharmacokinetics and urinary recovery of intravesically administered gemcitabine. Proc. Am. Soc. Clin. Oncol. 90a (2002) (Abstract 359).
58. Dalbagni G, Russo P, Sheinfeld J et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. J. Clin. Oncol. 20, 3193-3198 (2002).
59. Crawford ED. Intravesical therapy for superficial cancer: need for more options. J. Clin. Oncol. 20, 3185-3186 (2002).